Novel Opioid Therapy Without the Addiction Potential

Technology #ua16-187

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Victor Hruby
Regents Professor Emeritus, Chemistry & Biochemistry
Ruben Vardanyan
Research Professor, Chemistry & Biochemistry
Managed By
Paul Eynott
Sr. Licensing Manager (520) 621-2878

Title: Bivalent Ligands Modulating Mu- and Delta Receptors Simultaneously as Medications for Chronic Pain Treatment

 

Invention: The invention is a novel compound that modulates both the mu and delta opioid receptors and maintains analgesia while reducing the negative side effects.

Background: The number of Americans affected by acute and chronic pain in 2016 is expected to reach 26.7 million and 34.8 million respectively. Unfortunately, because pain is often treated with opioids, users have a substantial risk of becoming physically dependent on their medication. High doses of opioids can also result in side effects such as constipation, nausea, vomiting, and respiratory depression. This novel technology has the potential to fill a niche by providing a new drug with the promise of low addiction potential.

 

Applications:

  • Creation of a new drug to treat acute and chronic pain

 

Advantages:

  • Reduces the negative side effects associated with opioids
  • Maintains analgesia
  • Modulates the mu and delta opioid receptors
  • Potential to provide an addiction-free painkiller

 

Licensing Manager: 

Paul Eynott

PaulE@tla.arizona.edu

(520) 471-3612